Designer combination therapy for cancer

Nature Biotechnology

Volumn 24, Issue 2, 2006, Pages 163-164

  Lane, David ^a  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; CHEMOTHERAPY;

ANTI-CANCER STRATEGY; CELL-SURFACE PROTEINS;

TUMORS;

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CELL SURFACE PROTEIN; IRINOTECAN; METHYL AURISTATIN E; TRASTUZUMAB; UNCLASSIFIED DRUG;

CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; FLUORESCENCE; GENETIC ENGINEERING; HUMAN; INTERNALIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RNA ISOLATION; SHORT SURVEY; TUMOR REGRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; DRUG DESIGN; FEMALE; HUMANS; IMMUNOTHERAPY; MEMBRANE PROTEINS; MICE; MICE, NUDE; TREATMENT OUTCOME;

EID: 32444447066     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0206-163     Document Type: Short Survey

References (7)

1. Rougier, P. & Lepere, C. Semin. Oncol. 32, 15-20 (2005).
2. Decker, S. & Sausville, E.A. Ann. NY Acad. Sci. 1059, 61-69 (2005).
3. Romond, E.H. et al. N. Engl. J. Med. 353, 1673-1684 (2005).
4. Adams, G.P. & Weiner, L.M. Nat. Biotechnol. 23, 1147-1157 (2005).
5. Rubinfeld, B. et al. Nat. Biotechnol. 24, 205-209 (2006).
6. Quak, J.J. et al. Am. J. Pathol. 136, 191-197 (1990).
7. de Bree, R., Roos, J.C., Verel, I., van Dongen, G.A. & Snow, G.B. Oral. Dis. 9, 241-248 (2003).